FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2308121640> ?p ?o ?g. }

• W2308121640 abstract "e19523 Background: Preclinical data show that PLD and bortezomib demonstrate synergistic anti-MM effects. Clinical trials have demonstrated the efficacy of this combination for MM patients (pts) as well as its superiority to bortezomib alone. In vivo studies have shown that more frequent administration of low-dose PLD produces enhanced anti-MM effects with better tolerability compared to weekly standard doses of PLD. Thus, a low dose PLD dosing schedule was evaluated in combination with bortezomib and dexamethasone for pts with R/R MM. Methods: This retrospective analysis sought to evaluate the DVD regimen for pts with R/R MM. Twenty pts who had received and failed at least one prior treatment for MM were studied. Treatment consisted of intravenous administration of 40 mg dexamethasone, 1.0 mg/m 2 bortezomib and 5.0 mg/m 2 PLD on days 1, 4, 8 and 11 of a 28-day cycle. Pts ranged in age from 43–81 years (median 65), and had received between 1–14 prior therapies (median 5). Baseline disease stage was: 6 (I), 7 (II), and 7 (III). Elevated serum creatinine levels at baseline were found in 30% of patients. Results: The objective response rate (ORR) was 50%, which included 1 complete response (5%), 1 very good partial response (5%), 4 partial responses (20%), and 4 minimal responses (20%). Sixteen pts had previously received bortezomib-containing regimens and 6 (38%) responded. Among the entire cohort, the duration of response was 2+-19+ months (mo) (median 7 mo). Six pts had stable disease (30%) lasting between 5–9 mo (median 9 mo). Progression-free survival was 1+-19+ mo (median 8 mo). The regimen was well tolerated with a single mild case of transient hand and foot syndrome and 10 pts developed grade 1 or 2 peripheral neuropathy. One pt discontinued the regimen due to an adverse event (AE; 5%). The median overall survival was 17 mo (range 1+-33+ mo). Conclusions: Patients treated with the DVD regimen in this study who had failed many prior regimens (median 5) with progressive disease demonstrated a high response rate (50%). In addition, there were few significant or drug-related AEs. Because of these encouraging results, we are now evaluating this regimen in a phase 2 clinical trial in the frontline setting. [Table: see text]" @default.
• W2308121640 created "2016-06-24" @default.
• W2308121640 creator A5021554856 @default.
• W2308121640 creator A5039897310 @default.
• W2308121640 creator A5040835019 @default.
• W2308121640 creator A5048382573 @default.
• W2308121640 creator A5054387621 @default.
• W2308121640 date "2009-05-20" @default.
• W2308121640 modified "2023-09-27" @default.
• W2308121640 title "A retrospective review of pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone (DVD) for relapsed or refractory (R/R) multiple myeloma (MM)" @default.
• W2308121640 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e19523" @default.
• W2308121640 hasPublicationYear "2009" @default.
• W2308121640 type Work @default.
• W2308121640 sameAs 2308121640 @default.
• W2308121640 citedByCount "0" @default.
• W2308121640 crossrefType "journal-article" @default.
• W2308121640 hasAuthorship W2308121640A5021554856 @default.
• W2308121640 hasAuthorship W2308121640A5039897310 @default.
• W2308121640 hasAuthorship W2308121640A5040835019 @default.
• W2308121640 hasAuthorship W2308121640A5048382573 @default.
• W2308121640 hasAuthorship W2308121640A5054387621 @default.
• W2308121640 hasConcept C121332964 @default.
• W2308121640 hasConcept C126322002 @default.
• W2308121640 hasConcept C126894567 @default.
• W2308121640 hasConcept C141071460 @default.
• W2308121640 hasConcept C142424586 @default.
• W2308121640 hasConcept C197934379 @default.
• W2308121640 hasConcept C2776364478 @default.
• W2308121640 hasConcept C2776694085 @default.
• W2308121640 hasConcept C2777478702 @default.
• W2308121640 hasConcept C2778375690 @default.
• W2308121640 hasConcept C2778822529 @default.
• W2308121640 hasConcept C2780401358 @default.
• W2308121640 hasConcept C2781413609 @default.
• W2308121640 hasConcept C71924100 @default.
• W2308121640 hasConcept C87355193 @default.
• W2308121640 hasConcept C90924648 @default.
• W2308121640 hasConcept C98274493 @default.
• W2308121640 hasConceptScore W2308121640C121332964 @default.
• W2308121640 hasConceptScore W2308121640C126322002 @default.
• W2308121640 hasConceptScore W2308121640C126894567 @default.
• W2308121640 hasConceptScore W2308121640C141071460 @default.
• W2308121640 hasConceptScore W2308121640C142424586 @default.
• W2308121640 hasConceptScore W2308121640C197934379 @default.
• W2308121640 hasConceptScore W2308121640C2776364478 @default.
• W2308121640 hasConceptScore W2308121640C2776694085 @default.
• W2308121640 hasConceptScore W2308121640C2777478702 @default.
• W2308121640 hasConceptScore W2308121640C2778375690 @default.
• W2308121640 hasConceptScore W2308121640C2778822529 @default.
• W2308121640 hasConceptScore W2308121640C2780401358 @default.
• W2308121640 hasConceptScore W2308121640C2781413609 @default.
• W2308121640 hasConceptScore W2308121640C71924100 @default.
• W2308121640 hasConceptScore W2308121640C87355193 @default.
• W2308121640 hasConceptScore W2308121640C90924648 @default.
• W2308121640 hasConceptScore W2308121640C98274493 @default.
• W2308121640 hasLocation W23081216401 @default.
• W2308121640 hasOpenAccess W2308121640 @default.
• W2308121640 hasPrimaryLocation W23081216401 @default.
• W2308121640 hasRelatedWork W1996748901 @default.
• W2308121640 hasRelatedWork W2244503020 @default.
• W2308121640 hasRelatedWork W230412469 @default.
• W2308121640 hasRelatedWork W2364188423 @default.
• W2308121640 hasRelatedWork W2379244710 @default.
• W2308121640 hasRelatedWork W2531713994 @default.
• W2308121640 hasRelatedWork W3029718857 @default.
• W2308121640 hasRelatedWork W3134875278 @default.
• W2308121640 hasRelatedWork W4241469660 @default.
• W2308121640 hasRelatedWork W4313857557 @default.
• W2308121640 isParatext "false" @default.
• W2308121640 isRetracted "false" @default.
• W2308121640 magId "2308121640" @default.
• W2308121640 workType "article" @default.